What question did this study set out to answer?

Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prospective, Observational Cohort Study

View Full Paper

Ask AI

Bookmark

This research aims to compare the effectiveness and safety of doravirine, lamivudine, and tenofovir disoproxil fumarate versus bictegravir, emtricitabine, and tenofovir alafenamide in adults with HIV who switched from efavirenz-based regimens.
Single-center, real-world, prospective observational cohort study
Participants aged ≥18 with virological suppression on efavirenz for ≥6 months
Stratification based on clinical decisions to switch to DOR/3TC/TDF or BIC/FTC/TAF
Primary endpoint measured HIV-1 RNA levels at week 48
DOR group had 2 (1.4%) and BIC group had 1 (0.5%) with HIV-1 RNA ≥50 copies/mL at 48 weeks
CD4 counts decreased by ∼76.5 cells/µL in the BIC group at week 48
DOR group showed a 0.453 mmol/L reduction in triglycerides compared to baseline
Body weight change in DOR group was 1.8 kg lower than in BIC group at week 48

No takes yet. Share an insight, caveat, or question.

A prospective cohort study shows doravirine maintains virological suppression in adults with HIV, indicating safety benefits.

Li et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark